Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis
Background: Perioperative chemotherapy (CT) is an established therapeutic approach for patients diagnosed with stage IB–III gastric cancer (GC). Objectives: This study aimed to investigate the efficacy of this approach in individuals with GC exhibiting high microsatellite instability (MSI-H). Design...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-02-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241231259 |
| _version_ | 1827337688518230016 |
|---|---|
| author | Fausto Petrelli Maria Antista Francesca Marra Fulvia Milena Cribiu’ Valentina Rampulla Filippo Pietrantonio Lorenzo Dottorini Michele Ghidini Andrea Luciani Alberto Zaniboni Gianluca Tomasello |
| author_facet | Fausto Petrelli Maria Antista Francesca Marra Fulvia Milena Cribiu’ Valentina Rampulla Filippo Pietrantonio Lorenzo Dottorini Michele Ghidini Andrea Luciani Alberto Zaniboni Gianluca Tomasello |
| author_sort | Fausto Petrelli |
| collection | DOAJ |
| description | Background: Perioperative chemotherapy (CT) is an established therapeutic approach for patients diagnosed with stage IB–III gastric cancer (GC). Objectives: This study aimed to investigate the efficacy of this approach in individuals with GC exhibiting high microsatellite instability (MSI-H). Design: A systematic review was conducted, including studies that provided data on (neo)adjuvant CT outcomes in patients with MSI-H GC. Methods: Systematic searches were conducted in PubMed, Cochrane Central of Controlled Trials, and Embase databases. Data were aggregated using hazard ratios (HRs) to compare overall survival between CT and surgery. Results: Data analysis from 23 studies, including 22,011 patients, revealed that the prevalence of MSI-H is 9.8%. Administration of adjuvant or perioperative CT did not significantly reduce the risk of death or relapse in patients with MSI-H GC (HR = 0.8, 95% CI 0.54–1.16; p = 0.24 and HR = 0.84, 95% CI 0.59–1.18; p = 0.31, respectively). Conclusion: Chemotherapy did not benefit patients diagnosed with MSI-H nonmetastatic GC but rather will be integrated with immune checkpoint inhibitors in the near future. |
| first_indexed | 2024-03-07T18:59:53Z |
| format | Article |
| id | doaj.art-e83636b6e76e40ea8837189179a8dafe |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-03-07T18:59:53Z |
| publishDate | 2024-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-e83636b6e76e40ea8837189179a8dafe2024-03-01T19:04:26ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592024-02-011610.1177/17588359241231259Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysisFausto PetrelliMaria AntistaFrancesca MarraFulvia Milena Cribiu’Valentina RampullaFilippo PietrantonioLorenzo DottoriniMichele GhidiniAndrea LucianiAlberto ZaniboniGianluca TomaselloBackground: Perioperative chemotherapy (CT) is an established therapeutic approach for patients diagnosed with stage IB–III gastric cancer (GC). Objectives: This study aimed to investigate the efficacy of this approach in individuals with GC exhibiting high microsatellite instability (MSI-H). Design: A systematic review was conducted, including studies that provided data on (neo)adjuvant CT outcomes in patients with MSI-H GC. Methods: Systematic searches were conducted in PubMed, Cochrane Central of Controlled Trials, and Embase databases. Data were aggregated using hazard ratios (HRs) to compare overall survival between CT and surgery. Results: Data analysis from 23 studies, including 22,011 patients, revealed that the prevalence of MSI-H is 9.8%. Administration of adjuvant or perioperative CT did not significantly reduce the risk of death or relapse in patients with MSI-H GC (HR = 0.8, 95% CI 0.54–1.16; p = 0.24 and HR = 0.84, 95% CI 0.59–1.18; p = 0.31, respectively). Conclusion: Chemotherapy did not benefit patients diagnosed with MSI-H nonmetastatic GC but rather will be integrated with immune checkpoint inhibitors in the near future.https://doi.org/10.1177/17588359241231259 |
| spellingShingle | Fausto Petrelli Maria Antista Francesca Marra Fulvia Milena Cribiu’ Valentina Rampulla Filippo Pietrantonio Lorenzo Dottorini Michele Ghidini Andrea Luciani Alberto Zaniboni Gianluca Tomasello Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis Therapeutic Advances in Medical Oncology |
| title | Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis |
| title_full | Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis |
| title_fullStr | Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis |
| title_full_unstemmed | Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis |
| title_short | Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis |
| title_sort | adjuvant and neoadjuvant chemotherapy for msi early gastric cancer a systematic review and meta analysis |
| url | https://doi.org/10.1177/17588359241231259 |
| work_keys_str_mv | AT faustopetrelli adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT mariaantista adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT francescamarra adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT fulviamilenacribiu adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT valentinarampulla adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT filippopietrantonio adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT lorenzodottorini adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT micheleghidini adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT andrealuciani adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT albertozaniboni adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis AT gianlucatomasello adjuvantandneoadjuvantchemotherapyformsiearlygastriccancerasystematicreviewandmetaanalysis |